Mr. Slavin is the founding CEO of Fuzionaire and Fuzionaire Diagnostics. Outside of Fuzionaire, he is the founder and chairman of the Slavin Family Foundation, whose fellowships support some of the world’s top student entrepreneurs, and the founder of EES Ventures, a seed-stage venture capital firm. With Nova Spivack, Mr. Slavin is also a co-founder of the Arch Mission Foundation, a nonprofit creating multiple redundant repositories of human knowledge and biology in space. The Arch Mission created the first permanent library in solar orbit in February 2018 as part of SpaceX’s Falcon Heavy test launch, and landed the Lunar Library on the Moon in 2019. Previously, Mr. Slavin spent six years at top-ranked law firm Skadden Arps, focusing on public and private mergers and acquisitions. He holds a BA from Yale, magna cum laude and Phi Beta Kappa, where he graduated at 19, and a JD from Harvard Law School.
We are on a mission to improve disease diagnoses and treatments, helping people live longer, healthier lives.
With PET, the barriers to better imaging are largely the result of basic limitations in chemistry. Leveraging a breakthrough in alkali metal catalysis, Fuzionaire Dx is working to improve the scope, safety, use, and cost of PET imaging.
Fuzionaire Dx is a radiopharmaceutical company. Our radiolabeling platform aims to unlock the power of PET to help detect and treat any disease and improve the drug discovery process.
We make it possible to rapidly produce a broad range of fluorine-18 radiopharmaceuticals based on a single, catalyst-driven, disease-agnostic platform. Our technology offers researchers and clinicians a new strategy to detect, localize, diagnose, and monitor more diseases, earlier, and with unprecedented precision.
The platform also has the potential to become a unique tool for drugmakers, providing critical in vivo pharmacological data earlier in the drug discovery process.
As a team of chemists, biophysicists, molecular scientists, and entrepreneurs, our mission is to unlock the power of PET to improve the human condition.
Fuzionaire Dx is led by a close-knit team of managers and world-class experts advising the company.
Nick SlavinCo-Founder and CEOFuzionaire Dx
Anton Toutov PhDCo-FounderFuzionaire Dx
Dr. Toutov holds a PhD in organic chemistry from Caltech in the laboratory of Nobel Laureate Robert H. Grubbs, where he held Dow-Resnick, NSERC, and Bristol-Myers Squibb fellowships. Dr. Toutov collectively has over 40 scholarly articles and patent grants and applications to his name spanning the fields of chemical synthesis, clean energy, and drug discovery. Among them is the discovery of a new form of catalysis, which was first published in Nature and was later presented to general audiences in the documentary film Element 19. He is the recipient of the 2016 Demetriades Caltech Thesis Prize, the 2015 Alfred Bader Award for Student Innovation (Sigma-Aldrich Corporation), the 2014 Dow Chemical Sustainability Challenge Grand Prize, and the 2014 Milliken & Co. “Deep Science” award, among others. Dr. Toutov also serves as senior technical advisor to the Gates Foundation-backed Medicines for All Institute, improving access to affordable, high-quality medicines.
Nova SpivackCo-FounderFuzionaire Dx
Mr. Spivack is a serial entrepreneur, technology futurist, and co-founder of the in house incubator of Stanford Research Institute (SRI) and Sarnoff Laboratories, which launched SIRI (acquired by Apple). He is the founder and CEO of the early stage science and technology incubator, Magical, and is co-founder and chairman of the Arch Mission Foundation. Previously, Mr. Spivack was CEO of Bottlenose, a leader in real-time data analytics. He founded Radar Networks in 2003, business incubator Lucid Ventures in 2001, and in 1994 he co-founded EarthWeb, Inc., one of the first web start-ups (record-breaking IPO in 1998) and spinout Dice.com (IPO in 2007). He is also a co-founder or early investor in The Daily Dot, Klout (acquired by Lithium), and a number of applied and life science companies including Space Adventures and Cambrian Genomics. Mr. Spivack is an inventor on nearly 100 granted and pending patents.
Ryan Clark PhDDirector of Discovery ChemistryFuzionaire Dx
Dr. Clark is a medicinal chemist with experience leading multidisciplinary teams in the discovery of small molecule drug candidates. These novel compounds targeting enzymes, G protein-coupled receptors, nuclear hormone receptors, kinases and protein–protein interactions have spanned therapeutic areas including multiple sclerosis, oncology, virology, inflammation and fibrosis. Born out of careful multifactorial optimization and practical creativity, his discoveries have furthered the understanding of potential therapeutic targets and contributed to the advancement of multiple research programs. One of these discoveries, TPST-1120, a first-in-class PPARα (peroxisome proliferator-activated receptor alpha) antagonist, is being evaluated in a Phase I/Ib clinical trial to examine its impact on advanced-stage malignancies. Dr. Clark holds a PhD in chemistry from The Scripps Research Institute where he worked with Professor Dale Boger.
Fred Chin PhDAdvisory BoardStanford
Dr. Chin is Head of Cyclotron Radiochemistry and Assistant Professor of Radiology at Stanford University School of Medicine, where he researches and develops novel imaging agents and therapeutics with a focus on PET imaging. Closely linked with Stanford Health Care, Dr. Chin’s group provides more than 20 doses of 18F-FDG daily for standard-of-care PET imaging, and has brought or is in the process of bringing more than a dozen other tracers to the clinic. His group is involved in the arc of drug development, from research on the benchtop to translational first-in-human clinical studies, primarily using radiolabeled 18F and 11C tracers. Much of his interest lies in developing tracers to image the mysterious diseases of the brain (e.g., pain, addiction, Parkinson’s disease, Alzheimer’s disease, glioblastoma) or other cancers.
Jacob Hooker PhDAdvisory BoardHarvard Medical School
Dr. Hooker is a Professor of Radiology at Harvard Medical School and Director of Radiochemistry at the Martinos Center for Biomedical Imaging. He is also the Phyllis and Jerome Lyle Rappaport MGH Research Scholar and an Associate Neuroscientist at Massachusetts General Hospital, and an associate editor for ACS Chemical Neuroscience. Dr. Hooker’s lab has the mission of accelerating the study of the living human brain and nervous system through development and application of molecular imaging agents. The lab has developed and patented several imaging technologies for neuroscience, including a first-in-class radiotracer for neuroepigenetic imaging. Dr. Hooker was an inaugural recipient of the Talented 12 Award by C&E News, was named a Kavli Fellow by the National Academy of Sciences, has received a NARSAD Independent Investigator Award, and was awarded the Presidential Early Career Award for Scientists and Engineers by President Obama.
Dennis Liotta PhDAdvisory BoardEmory
Dr. Liotta is the Samuel Candler Dobbs Professor of Chemistry at Emory University and Executive Director of the Emory Institute for Drug Development. Through his discoveries, Dr. Liotta has helped to transform HIV/AIDS from a death sentence to a chronic infection. Over 90% of all of the HIV-infected persons in the United States have taken one of the drugs he invented. Dr. Liotta is an inventor on 75 issued US patents, many of which cover the antiviral and anticancer drugs and drug candidates he has discovered. He is the co-founder of numerous companies, two of which were acquired by Gilead Pharmaceuticals. He is recognized as one of the premier discoverers of novel therapeutics in the United States, having been an inventor of 10 FDA approved therapeutics including Epivir, Combivir, Trizivir, Epzicom, Epivir-HBV, Emtriva, Truvada, Atripla, Complera and Stribid.
Douglas Scherr MDAdvisory BoardWeill Cornell
Dr. Scherr is a Professor of Urology and the Clinical Director of Urologic Oncology at the Weill Medical College of Cornell University. Dr. Scherr’s clinical focus is the treatment of urologic malignancies – in particular, the treatment of prostate cancer, bladder cancer, kidney cancer, and testicular cancers, as well as genitourinary and retroperitoneal sarcomas. He was the first physician at Cornell to perform a robotic prostatectomy, and travels nationally and internationally teaching the procedure to urologic surgeons. He has been active in the development of optical coherence tomography and its application to urologic imaging, and patented and developed the concept of “multiphoton endoscopy,” which utilizes high-speed laser energy to create high quality microscopic images of human tissue.
Kristin Swanson PhDAdvisory BoardMayo Clinic
Dr. Swanson is a Professor and Vice Chair for Research in the Department of Neurologic Surgery at Mayo Clinic. She is also Director of the Mathematical Neuro-Oncology Laboratory and Co-Director of the Precision Neurotherapeutics Innovation Program at Mayo Clinic. Dr. Swanson is a quantitative cancer researcher (mathematical oncologist) whose research lab has pioneered the burgeoning field of Mathematical Neuro-Oncology, developing patient-specific mathematical models of glioma to assess and predict disease course and optimize treatment. The lab works with clinical and research teams at Mayo Clinic to bring these innovations to the clinic while identifying new predictive models. Dr. Swanson’s research has been supported through funding by the NIH, numerous foundations, the James D. Murray Endowed Chair at the University of Washington, TGen, and the Mayo Clinic.
Christopher Waldmann PhDAdvisory BoardUniversity of Mainz
Dr. Waldmann is Head of Radiochemistry at the University Medical Center Mainz, Germany. He and his team provide the Department of Nuclear Medicine in Mainz as well as other healthcare institutions in the region with radiopharmaceuticals for PET imaging and therapeutic applications. As a postdoc at UCLA’s Crump Institute for Molecular Imaging, Dr. Waldmann played a central role in the original HetSiFA discovery work, in collaboration with the laboratory of Nobel Laureate Robert H. Grubbs at Caltech, that constitutes the scientific basis of Fuzionaire Diagnostics. At the Biomedical Cyclotron facility at UCLA, he was involved in the production of PET radiopharmaceuticals for clinical trials, with scientific collaborators including Professors Anna Wu, Michael van Dam, and David Shackelford. His radiochemical research focuses on the development and clinical implementation of 18F-labeled radiopharmaceuticals for the noninvasive detection of cancer. Dr. Waldmann is author of a chapter in the textbook Molecular Imaging in Oncology, and his work has been published in leading academic journals including Nature.
As we enter the world of precision medicine, Fuzionaire Diagnostics provides technology that could help track and image cancers in an unprecedented way, which will ultimately allow for many novel approaches in cancer therapeutics.
Expanding the bounds of how we diagnose, study, and treat disease
We are continuously exploring additional clinical applications of our radiolabeling platform.
- Our heterocyclic chemistry enables radiopharmaceuticals that combine diagnostic and therapeutic approaches
- Accelerating radiopharmaceutical discovery through combinatorial synthesis of radiotracer libraries
- Pioneering new engineering solutions that combine flow chemistry, synthesis electrification, and automation
Get in touch
If you are interested in learning more about our radiolabeling platform, we want to hear from you.Contact